These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1971604)

  • 21. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Maton PN; Gardner JD; Jensen RT
    Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion.
    Metz DC; Soffer E; Forsmark CE; Cryer B; Chey W; Bochenek W; Pisegna JR
    Am J Gastroenterol; 2003 Feb; 98(2):301-7. PubMed ID: 12591045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of omeprazole on acid secretion and acid-related symptoms in patients with Zollinger-Ellison syndrome.
    Bardram L; Stadil F
    Scand J Gastroenterol Suppl; 1989; 166():95-100; discussion 111-3. PubMed ID: 2574912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high.
    Metz DC; Pisegna JR; Fishbeyn VA; Benya RV; Feigenbaum KM; Koviack PD; Jensen RT
    Gastroenterology; 1992 Nov; 103(5):1498-508. PubMed ID: 1426868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study.
    Lloyd-Davies KA; Rutgersson K; Sölvell L
    Aliment Pharmacol Ther; 1988 Feb; 2(1):13-32. PubMed ID: 2979229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review article: the management of Zollinger-Ellison syndrome.
    Maton PN
    Aliment Pharmacol Ther; 1993 Oct; 7(5):467-75. PubMed ID: 7904187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Present experiences with omeprazole in the Zollinger-Ellison syndrome.
    Lamers CB
    Scand J Gastroenterol Suppl; 1986; 118():123-8. PubMed ID: 3460167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.
    Lambers CB; Lind T; Moberg S; Jansen JB; Olbe L
    N Engl J Med; 1984 Mar; 310(12):758-61. PubMed ID: 6142418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients.
    Tomassetti P; Salomone T; Migliori M; Campana D; Corinaldesi R
    Drugs Aging; 2003; 20(14):1019-34. PubMed ID: 14651442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changing patterns in presentation and management of the Zollinger-Ellison syndrome in Northern Ireland, 1970-1988.
    Collins JS; Buchanan KD; Kennedy TL; Johnston CF; Ardill JE; Sloan JM; McIlrath EM; Russell C
    Q J Med; 1991 Mar; 78(287):215-25. PubMed ID: 1675471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis and management of the Zollinger-Ellison syndrome.
    Jensen RT; Pandol SJ; Collen MJ; Raufman JP; Gardner JD
    J Clin Gastroenterol; 1983; 5 Suppl 1():123-31. PubMed ID: 6140281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.
    Metz DC; Comer GM; Soffer E; Forsmark CE; Cryer B; Chey W; Pisegna JR
    Aliment Pharmacol Ther; 2006 Feb; 23(3):437-44. PubMed ID: 16423003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical management of patients with Zollinger-Ellison syndrome who have had previous gastric surgery: a prospective study.
    Maton PN; Frucht H; Vinayek R; Wank SA; Gardner JD; Jensen RT
    Gastroenterology; 1988 Feb; 94(2):294-9. PubMed ID: 3335308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Application of proton pump inhibitor to special conditions; Zollinger-Ellison syndrome].
    Tani N
    Nihon Rinsho; 1992 Jan; 50(1):154-9. PubMed ID: 1347327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy.
    Weber HC; Venzon DJ; Jensen RT; Metz DC
    Gastroenterology; 1997 Jan; 112(1):84-91. PubMed ID: 8978346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long-term efficacy and tolerability of omeprazole in 20 patients with severe Zollinger-Ellison syndrome].
    Cadranel JF; Ruszniewski P; Elouaer-Blanc L; Lehy T; Delchier JC; Cadiot G; Florent C; Vatier J; Mignon M
    Gastroenterol Clin Biol; 1989; 13(8-9):654-62. PubMed ID: 2806801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Famotidine: effective treatment of Zollinger-Ellison syndrome.
    Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
    J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells.
    Maton PN; Lack EE; Collen MJ; Cornelius MJ; David E; Gardner JD; Jensen RT
    Gastroenterology; 1990 Oct; 99(4):943-50. PubMed ID: 1697548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.